NeuroBo Pharmaceuticals, Inc. announced on January 14, 2022, Mr. Douglas J. Swirsky provided notice of his resignation from the Board of Directors, effective immediately. Andrew I. Koven, a current director of the Company was elected Chairman of the Board and Michael Salsbury, a current director of the Company was appointed to the Audit Committee of the Board and appointed Chairman of the Audit Committee. As a result, the Audit Committee of the Board currently consists of Jason Groves, Andrew I. Koven, Michael Salsbury.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.84 USD | +0.83% |
|
+18.05% | +30.93% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.93% | 23.55M | |
+15.20% | 122B | |
+19.67% | 113B | |
+18.95% | 26.49B | |
-23.86% | 19.4B | |
-19.03% | 16.24B | |
-20.90% | 15.4B | |
-46.14% | 15.15B | |
+63.85% | 14.93B | |
+4.49% | 13.52B |
- Stock Market
- Equities
- NRBO Stock
- News NeuroBo Pharmaceuticals, Inc.
- Neurobo Pharmaceuticals, Inc. Announces Management Changes